All In Biotech

Drug Trial Radar · NCT07409272

A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer

A Phase 3, Double-blind, Placebo-controlled, Randomized Study to Assess the Efficacy and Safety of ASP3082 in Combination With mFOLFIRINOX or NALIRIFOX as First-line Treatment in Participants With KRAS G12D Mutated Metastatic Pancreatic Adenocarcinoma

Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 614 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

614

Planned (sponsor's estimate)

Start

Feb 17, 2026

Primary completion

Aug 31, 2029

Study completion Aug 31, 2029

Sponsor

Lead sponsor
Astellas Pharma Global Development, Inc.Astellas (ALPMY)
Sponsor type
Industry
First posted
Feb 13, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Pancreatic cancer is difficult to diagnose early. By the time people have been diagnosed, the cancer has usually spread to other parts of the body (metastatic). The standard treatment is chemotherapy, but other treatments are needed to improve outcomes in people with pancreatic cancer. The first treatment that people usually receive is chemotherapy. At the time this study started, some of the main standard chemotherapies for pancreatic cancer were mFOLFIRINOX or NALIRIFOX. Genes give your body instructions on how to make proteins. Proteins are needed to keep the body working properly. Many types of cancer are caused by changes in certain genes, making them faulty. Many people with pancreatic cancer have a faulty KRAS gene. One such change in the KRAS gene is called a G12D mutation. Researchers are looking for ways to stop the actions of abnormal proteins made from the KRAS G12D mutation. This study is about setidegrasib given with chemotherapy in people with pancreatic cancer who have the KRAS G12D mutation. Before setidegrasib can become an approved treatment, clinical studies need to be completed to understand how it works and how safe it is. The main aim is to learn if people who are given setidegrasib with chemotherapy live for longer than people who are given placebo with chemotherapy. Other aims are to learn if setidegrasib delays the cancer and symptoms returning, how the body processes setidegrasib, and its safety, when given with chemotherapy. People in this study will be adults with metastatic pancreatic cancer with the G12D mutation in their KRAS gene. Surgery or radiotherapy will not be an option to cure their cancer. People cannot take part if the cancer cells have spread to the thin tissue covering the brain and spinal cord (leptomeningeal disease), have symptoms of cancer in the brain or nervous system, or have recently had some other cancers that required treatment. In this study, people are given either setidegrasib with mFOLFIRINOX or NALIRIFOX chemotherapy, or a placebo with mFOLFIRINOX or NALIRIFOX chemotherapy. Whether people receive setidegrasib or placebo is decided by chance. The study doctor decides which chemotherapy (mFOLFIRINOX or NALIRIFOX) people receive. People will only receive NALIRIFOX chemotherapy (with setidegrasib or placebo) after the safety of setidegrasib with NALIRIFOX chemotherapy has been confirmed in another ongoing setidegrasib study. All of the study treatments are given slowly through a tube into a vein (infusion). People will continue to receive study treatment until their cancer gets worse, they can't tolerate the study treatment, they start other cancer treatment, they or the doctor decides the person should stop receiving study treatment, or sadly they pass away. There will be safety checks at each visit, and the doctors will continue to check for medical problems and people's wellbeing throughout the study.

Conditions

  • Pancreatic Cancer
  • Metastatic Pancreatic Cancer
  • Metastatic Pancreatic Adenocarcinoma

Interventions

  • SetidegrasibDrug

    Intravenous infusion

  • OxaliplatinDrug

    Intravenous infusion

  • LeucovorinDrug

    Intravenous infusion

  • IrinotecanDrug

    Intravenous infusion

  • fluorouracilDrug

    Intravenous infusion

  • liposomal irinotecanDrug

    Intravenous infusion

  • PlaceboDrug

    Intravenous Infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Survival (OS)Time frame: Up to 3.5 years

Locations

104 sites in 11 countries. Site status is shown where the registry gives one.

  • Banner Gateway Medical Center - Banner MD Anderson Cancer Center

    Gilbert, Arizona · Recruiting

  • University of Arizona Cancer Center - North Campus

    Tucson, Arizona · Recruiting

  • Mercy Cancer Center

    Fort Smith, Arkansas · Recruiting

  • Crosson Cancer Institute at Providence St. Jude Medical Center in Fullerton

    Fullerton, California · Recruiting

  • UCI Health - Irvine

    Irvine, California · Recruiting

  • Cedars-Sinai - Cedars-Sinai Medical Center

    Los Angeles, California · Recruiting

  • Hoag Mem Hosp Presbyterian

    Newport Beach, California · Recruiting

  • UC Irvine Health-Chao Family Comprehensive Cancer Center

    Orange, California · Recruiting

  • Hartford Healthcare

    Hartford, Connecticut · Recruiting

  • Baptist MD Anderson Cancer Institute

    Jacksonville, Florida · Recruiting

  • Baptist Health Medical Group Oncology

    Miami, Florida · Recruiting

  • Mount Sinai Medical Center - Miami Beach

    Miami Beach, Florida · Recruiting

  • AdventHealth, Orlando

    Orlando, Florida · Recruiting

  • Piedmont Healthcare - Piedmont Physicians Medical Oncology Atlanta

    Atlanta, Georgia · Recruiting

  • Indiana University Health - Indiana University Melvin and Bren Simon Comprehensive Cancer Center

    Indianapolis, Indiana · Recruiting

  • Hematology Oncology of Indiana

    Indianapolis, Indiana · Recruiting

  • Saint Elizabeth Medical Center, Inc. DBA St. Elizabeth Health Care

    Edgewood, Kentucky · Recruiting

  • University of Maryland School - Division of Hematology/Oncology

    Baltimore, Maryland · Recruiting

  • University of Michigan Health - University of Michigan Medical Center

    Ann Arbor, Michigan · Recruiting

  • Henry Ford Cancer, Detroit

    Detroit, Michigan · Recruiting

  • Allina Health Cancer Institute - Hematology Cancer Care Services

    Minneapolis, Minnesota · Recruiting

  • HealthPartners Frauenshuh Cancer Center

    Saint Louis Park, Minnesota · Recruiting

  • HealthPartners Cancer Center at Regions Hospital

    Saint Paul, Minnesota · Recruiting

  • Mercy CH Chub O'Reilly Cancer Center

    Springfield, Missouri · Recruiting

  • The Alvin J. Siteman Cancer Center - Center for Advanced Med

    St Louis, Missouri · Recruiting

  • Mercy David C. Pratt Cancer Center - St. - Mercy Research - David C. Pratt Cancer Center

    St Louis, Missouri · Recruiting

  • Saint Joseph Hospital - Cancer Centers - St. Vincent Frontier Cancer Center

    Billings, Montana · Recruiting

  • Dartmouth Hitchcock Medical Center

    Lebanon, New Hampshire · Recruiting

  • Memorial Sloan Kettering - Hackensack - Memorial Sloan Kettering Basking Ridge

    Basking Ridge, New Jersey · Recruiting

  • Memorial Sloan Kettering Cancer Center - Monmouth

    Middletown, New Jersey · Recruiting

  • Memorial Sloan Kettering Bergen

    Montvale, New Jersey · Recruiting

  • Atlantic Health - Overlook Medical Center

    Morristown, New Jersey · Recruiting

  • Roswell Park Comprehensive Cancer Center

    Buffalo, New York · Recruiting

  • Memorial Sloan Kettering Commack

    Commack, New York · Recruiting

  • Memorial Sloan Kettering Westchester

    Harrison, New York · Recruiting

  • NYU Long Island Mineola

    Mineola, New York · Recruiting

  • Laura and Isaac Perlmutter Cancer Center at NYU Langone

    New York, New York · Recruiting

  • Memorial Sloan Kettering Cancer Center - Main Campus

    New York, New York · Recruiting

  • University of Rochester

    Rochester, New York · Recruiting

  • Stony Brook Medicine - Stony Brook Cancer Center

    Stony Brook, New York · Recruiting

Showing 40 of 104 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.